New combo therapy offers hope for rare bone marrow failure
NCT ID NCT07297550
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 21 times
Summary
This study tests a new drug (JAK1 inhibitor) combined with strong immune-suppressing therapy for people with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. The trial has two parts: first, a small safety test in patients who didn't improve with standard treatment, then a larger test in newly diagnosed patients. The goal is to see if the combination is safe and helps restore normal blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.